Member Info for HedgeHogarth

JHFH should not have to defend himself to anyone on here.

The SP in recent years would test anyone's patience and if he did sell a few 2 years ago (I can recall he did and it was well documented on this forum) good luck to him - especially if it helped him acquire a few more down the line.

JHFH is a serious LT holder and wished only the best for Hemo and has never knowingly shared anything on this forum that was not RNSd, shared by Vlad in a podcast / webinar or to the best of knowledge or judgement.

Unlike the many idiots on here who will try to twist anything to troll this board.

3 great updates from Vlad in last few months - A nice PR piece on TMSsearch, a brilliant webinar with Vlad on top form in which he really brought to life the progress and opportunities that Hemo are working on and a great update for the global scientific and investment audience too.

It makes me laugh all the low life imbeciles on here spouting absolute rubbish on this forum whilst trading in the background. Anyone who has done any research at all on this company will see your pathetic attempts for what they are.

The only transactions in Hemo shares I will be making in the foreseeable will be further top-ups. You'd have to really really REALLY need cash to want to sell at the current SP which for a number of factors does favourable value the company right now. But time will change...Lets' get clincial......

I was unable to attend the Webinar unfortunately due to work commitments

However i watched and listened last night and was literally blown away. I've always been a Vlad fan, but will openly admit that a small number of his updates have been a little vague.

BUT - this update for me was the best ever. He was able to articulate things so clearly - in a way in which if you knew nothing about Hemogenyx or the treatments they were working on you could understand what they are doing.

It was great to hear the progress made on Car-T - so may of the steps have been taken or prepared for. And i think i heard that both Hemo and Penn have proved til their blue in the face that this WORKS in the lab. And CarT is now a proven platform and therefore Hemo's number 1 focus right now.

Also great to hear that 2023 is targeted for CDX Clinical trials - even if it were to slip into early 2024 it is great to see Hemo have firm plans to go clinical on 2 fronts.

Finally, CBR. Hemo will be progressing this too over the next 18mths. Their new facility allows them to work with live viruses (unlike their previous lab).

So much to like here and remind me very loudly why i invested here.

This company was valued at multiples of today - perhaps those valuations were a bit OTT. But since McAP peaks the company is on such a stringer footing having made so much progress and has a clear strategy.

- 10k sq foot state of the art lab facility - clean rooms, ability to work with live virus, capability to manufacture CarT
- Cash in the bank to fund CarT and no plans for another placing. Hemo targeting non-dilutive funding options
- POC on CarT
- License to take CDX into Trials
- Well on the way to going into clinical trials with CarT

Correction - NOT buying anything right now

People are buying anything right now....spoke to a London broker last week who are holding 70% cash in their client portfolios

Show me a share that is not in the doldrums...
AO are now down 91 per cent vs their lockdown highs

So boring on here...
Nobody who has listened to Vlad or more knowledgeable posters on here should be expecting an imminent RNS.
Based on everything in the public domain - Its easy to know where Hemo are at right now
I'm looking forward to the Zoom call - I dont expect to learn much know, but may pick up a little more information

I was there...

Good to meet Peter and Andrew.

Also got a sneaky video tour of the new premises... Looking great. I expect photos and videos to be shared when Hemo are fully unpacked and ready...

Anyone going to AGM??

I was on call and it was very clear that IND was Q4/early Q1 - but that was not holding up progress ahead of that

Re: Share Price
Its at or close to rock bottom IMO. This is the time to buy, not wait until news. You wont be able to buy for less than 2p when IND in place
News on CBR partner could come at any time
Those looking to make a quick buck, maybe should look elsewhere.
SP cannot go much lower which is encouraging, and the rewards potential is huge.

LOL@ some of the comments on here by those happy to talk down this wonderful investment opportunity.

Nothing particularly new in Vlads update - but given the comments maybe he does need to keep recapping!

Its been clear to me for a while now that IND will drop in Q4, maybe even slightly into new year.

Go and read the Tortoise and the Hare

Vlad at his best...
Candid, honest, authentic and enthused

Pumpky - you are such a plank!

I'm all set for the AGM - anyone else planning on attending?

I'm voting too :-)

No news does not mean no progress

We know the company are working 100% towards CarT and doing all they can to make the trials successful.

Spot on Haywain...

When you are 70% down - you average is around 4.6p, That means you are already c3.2p down per share. So a further 0.1-0.3p movement does not make much difference IMO

The choices you have are to either stay patient because you are confident in the future prospects of the company, In the case of Hemo, this means backing the science, believing in the very significant commercial opportunities that scientific progress can bring, comfortable knowing there is a chance of additional shareholder dilution and knowing the odds of success at stages 1/2/ & 3 of clinical trials. (and trusting Vlad will steer Hemo in the right direction)

Or

Sell up if you think there are better places to invest your money.

I sit firmly in the first camp. I hope that Mr India holds to his word and puts a stop to the constant commentary on the daily SP. This SP will re-rate on a significant company update OR off the back of significant buying / speculation. The news could be days, weeks or months away. Its more important to me that Hemo do things well and get things right to be successful VS rushing and messing up. In the meantime I will accept the daily fluctuations of the SP as BAU supply and demand - It wont affect my medium to long term valuation in the slightest.

Re CBR...
Got the impression that it's likely we will get an update this year. Its the least developed of the three candidates.

The plan for CBR however is to continue to validate against real live viruses. So every chance of an update on that this year. Also, hemo have said they are unlikely to be able to see CBR through to its full potential on its own resources and are actively looking to partner with others to take it forwards.

Its incredibly exciting on a number of fronts for the future.

HT - happy to jump on a zoom call and share. But nothing more than a recap of what is in the RNS and perhaps a dip into the science.

One bit I will say that builds on the excitement around CBR - when submitting patents, there was some shock that this had not been done before and a proper check to validate that this exciting clinical candidate is new and very much Hemo's :-)

It perfectly conceivable that investment could flow off the back of the conference - particularly when the audience have had time to digest,

But they will be investing for medium and long term - NOT because they think something is imminent.

Vlad will not have shared anything with anyone to suggest news is imminent. Anything he or Hemo want to communicate will come through RNSs. When he does interviews, presentations or investor calls - its just a recap of what is in the publicly available RNSs

The RNS clearly lays out what is happening behind the scenes...

CarT - preparing for clinical trials and securing IND
CDX - preparing for clinical trails , however Ph1 unlikely to be before CarT trials. Next stage is testing on monkeys
CBR - Hemo actively looking for partner opportunities

CBR has huge potential, for me it's this candidate that may take us by surprise and result in a big RNS. That's not to discount CarT and CDX - i just think the next steps are a little more predictable.